Abstract
In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid β peptide (Aβ) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16, or 0.74%, reduced Ab accumulation by at least 40%. Seven of these compounds were confirmed to be effective in a secondary screen using each compound at a dose of 5 μM. Three of these seven compounds were more effective than the others at reducing Aβ levels in a tertiary screen, and led to 68 to 85% reductions in total Aβ, at the 25 μM dosage. The effects of these three drugs on secreted Aβ40, Aβ42, and sAPPα were also determined. Thus, we have identified lead compounds that may be useful for subsequent studies to determine the mechanism of action of each drug, as well as for pre-clinical studies to determine whether each of these drugs is safe and effective in vivo.
Keywords: amyloid peptide, drug screen, amyloid precursor protein
Current Alzheimer Research
Title: Drug Library Screen to Identify Compounds that Decrease Secreted Aβ from a Human Cell Line
Volume: 2 Issue: 2
Author(s): Enakshi Chakrabarti and Jonathan D. Smith
Affiliation:
Keywords: amyloid peptide, drug screen, amyloid precursor protein
Abstract: In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid β peptide (Aβ) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16, or 0.74%, reduced Ab accumulation by at least 40%. Seven of these compounds were confirmed to be effective in a secondary screen using each compound at a dose of 5 μM. Three of these seven compounds were more effective than the others at reducing Aβ levels in a tertiary screen, and led to 68 to 85% reductions in total Aβ, at the 25 μM dosage. The effects of these three drugs on secreted Aβ40, Aβ42, and sAPPα were also determined. Thus, we have identified lead compounds that may be useful for subsequent studies to determine the mechanism of action of each drug, as well as for pre-clinical studies to determine whether each of these drugs is safe and effective in vivo.
Export Options
About this article
Cite this article as:
Chakrabarti Enakshi and Smith D. Jonathan, Drug Library Screen to Identify Compounds that Decrease Secreted Aβ from a Human Cell Line, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585738
DOI https://dx.doi.org/10.2174/1567205053585738 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70)
Current Topics in Medicinal Chemistry Molecular Determinants of Fluoroquinolone Antibacterial Agents Pharmacokinetics
Current Clinical Pharmacology Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets Preface
Central Nervous System Agents in Medicinal Chemistry Acknowledgements to Reviewers:
Current Alzheimer Research Designing In Vitro Strategies and In Vivo Models for Alzheimer's Disease - Promises & Challenges
Current Alzheimer Research Therapeutic Strategies in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)
Central Nervous System Agents in Medicinal Chemistry Oxidative Stress and Neurodegenerative Diseases: Looking for a Therapeutic Solution Inspired on Benzopyran Chemistry
Current Topics in Medicinal Chemistry Migration and Function of Th17 Cells
Inflammation & Allergy - Drug Targets (Discontinued) Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design Environmental Enrichment as a Positive Behavioral Intervention Across the Lifespan
Current Neuropharmacology Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Medico-Legal Evaluation of Fatal Perinatal Asphyxia
Current Pediatric Reviews Metabolic Control of Glia-Mediated Neuroinflammation
Current Alzheimer Research Identifying the Structural Features of Pyrazolo[4,3-c]Quinoline-3-ones as Inhibitors of Phosphodiesterase 4: An Exploratory CoMFA and CoMSIA Study
Current Enzyme Inhibition Scaling Factors for the Extrapolation of In Vivo Metabolic Drug Clearance From In Vitro Data: Reaching a Consensus on Values of Human Micro-somal Protein and Hepatocellularity Per Gram of Liver
Current Drug Metabolism Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Current Alzheimer Research Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Quantitative Enzymology
Current Enzyme Inhibition Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?
CNS & Neurological Disorders - Drug Targets